Immune Cell mediated Spheroid Tumor Killing Assay (3D)

Overview of Immune Cells-Mediated Spheroid Tumor-Killing Assay (3D)

Three-dimensional (3D) in vitro cancer models derived from cancer cells and tumor tissues more closely resemble complex tumor biology and cellular interactions observed in vivo, which is a powerful tool to evaluate candidate immune cell products and accelerate preclinical drug development for cellular immunotherapies in solid tumor applications. The establishment of a 3D spheroid tumor-killing assay platform will have more profound significance for cancer drug development.

Fig.1 Multicellular tumor spheroids (MCTS) biology. (Kamatar, 2020)

Our Immune Cells-Mediated Spheroid Tumor-Killing Assay (3D) Service

Creative Biolabs is committed to providing comprehensive immune cells-mediated spheroid tumor-killing assay (3D) service with higher quality to meet global customers' needs.

In our immune cells-mediated spheroid tumor-killing assay (3D) service, cancer cell lines spheroids expressing special fluorescence were formed in 96-well U-plates. The test articles of interest and immune cells were then added to trigger the killing process. The vitality of the spheroid was determined over time by detecting the reduction of fluorescence. In addition, some cytokines may be added to the process to promote the response.

Fig.2 The workflow of our immune cells-mediated spheroid tumor-killing (3D) assay. (Creative Biolabs)

Highlights of Our Service

Abundant cell bank system

Multiple cancer cell lines.
Multiple Cell Sources.

Fast timeline

Two weeks to get reputable and high-quality final results.

Professional research team

Highly experienced scientists, high-quality equipment, and innovative technologies empower our service.

Customized service

one-stop service from sample processing to data visualization with the most up-to-date technical solutions provided.

Published Data

Here are some results displayed that refer to the drawings of immune cells-mediated spheroid tumor-killing assay (3D) articles.

1. 3D tumor spheroid microarray for high-throughput, high-content NK cell-mediated cytotoxicity

Fig.3 3D tumor spheroids killing assay (E: T = 10: 1). (Gopal, 2021)

Frequently Asked Questions

Q1: Is there any requirement for the number of cells in the experiment?

A1: The beginning quantity of tumor cells and the number of effector cells must be accurately regulated during the procedure. If the initial cell density is too high, the cells will rapidly destroy the PLL covering and create an adherent monolayer. A low cell count will result in substantial variability in spheroid size and quantity of spheroids per well. In addition, the ideal number of effector cells must be high enough to successfully eliminate tumor spheroids while also being as low as feasible to allow for the best imaging procedure possible.

Q2: If this assay can be applied to CART cytotoxicity characterization?

A2: Yes, this service enables the analysis of the 3D tumor spheroidal model's cytotoxicity mediated by CARTs.

For more details about our immune cells-mediated spheroid tumor-killing assay (3D) service, please don't hesitate to contact us for more information.

References

Kamatar, Advika, Gokhan Gunay, and Handan Acar. "Natural and synthetic biomaterials for engineering multicellular tumor spheroids." Polymers 12.11 (2020): 2506.
Distributed under Open Access License CC BY 4.0, without modification.
Gopal, Sneha, et al. "3D tumor spheroid microarray for high-throughput, high-content natural killer cell-mediated cytotoxicity." Communications Biology 4.1 (2021): 893.
Distributed under Open Access License CC BY 4.0. The original image was modified by extracting and using part C, and the title was changed to "3D tumor spheroids killing assay (E: T = 10: 1)".